Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Regeneron Pharmaceuticals Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $4.24, while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTZ | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $852.03 |
52-Week Low | $3.63 | $555.51 |
Market Cap | — | $83.43B |
Enterprise Value | — | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $4.04, up 8.46% in the last 24 hours, but technical indicators signal a bearish trend with moving averages and ADX strongly bearish. The stock lacks disclosed financial ratios, suggesting limited fundamental data availability. Recent news highlights ETFs betting against related stocks, indicating negative sentiment in its sector.
The outlook is cautious due to bearish technicals and sparse fundamentals. Risks include market volatility and competitive pressures, with no clear catalysts for upside. Investors should seek updated financial filings for a clearer assessment.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
